Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children (Q39308116)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

5

object named as

Glenda Gray

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1

object named as

Terry Nolan

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2

object named as

Lulu Bravo

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Ana Ceballos

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Essack Mitha

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Beatriz Quiambao

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sanjay S Patel

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Svetlana Bizjajeva

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Hans Bock

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Nancy Nazaire-Bermal

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Eduardo Forleo-Neto

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Giovanni Della Cioppa

12

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Vas Narasimhan

13

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

16 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

6146-6156

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Influenza and the rates of hospitalization for respiratory disease among infants and young children

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Socioeconomic impact of influenza on healthy children and their families

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Influenza-associated hospitalizations in the United States

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Vaccines for preventing influenza in healthy children

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The feasibility of universal influenza vaccination for infants and toddlers

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Epidemiology and pathogenesis of influenza

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Influenza vaccine--outmaneuvering antigenic shift and drift

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Influenza vaccine: the challenge of antigenic drift.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Influenza vaccines

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The mechanism of action of MF59 - an innately attractive adjuvant formulation

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Oil-in-water emulsion adjuvant with influenza vaccine in young children

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Epidemiology, Complications, and Cost of Hospitalization in Children With Laboratory-Confirmed Influenza Infection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

The evolution of human influenza viruses

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.08.068

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.08.068

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39308116&oldid=1896609117"